HOME >> BIOLOGY >> NEWS
Oregon Stem Cell Center result of OHSU research strides

PORTLAND, Ore. -- Oregon Health & Science University's fast-growing stem cell research program, which already has made significant strides in the hunt for human disease therapies, now has a place to call home.

The multidisciplinary Oregon Stem Cell Center, the first of its kind in the Northwest, is studying cell and gene therapy as an alternative to organ transplantation for pancreatic and liver disorders, diabetes, cancer and a host of other human diseases. Its focus will be on adult stem cells.

Launched in January, the center is housed among several laboratories on the Marquam Hill Campus, but it will occupy a single floor in the 270,000-square-foot Biomedical Research Building now under construction and to be completed in fall 2005.

Its director, Markus Grompe, M.D., professor of molecular and medical genetics, and pediatrics in the OHSU School of Medicine, said the center is a hub for all areas of OHSU's rapidly expanding stem cell biology program. It aims to maximize the potential of various stem cells as therapies for human diseases through a rapid, "bench-to-bedside" approach involving basic research in stem cell biology and preclinical trials of therapies in animal models, followed by human trials.

"This is something we needed but didn't have," said Grompe, who has long studied gene and cell therapy for metabolic genetic diseases, as well as the molecular genetics of a rare, cancer-susceptibility syndrome called Fanconi anemia. "The consensus here at OHSU is that this is an area that is going to be important."

While the center's offerings will widen over time to cover other diseases -- Parkinson's disease and diabetes are considered "hot" areas of stem cell research -- it will concentrate on two areas for now and "build on that."

"My idea is to focus on the liver and the pancreas, and focus on adult stem cells," he said. "Our research already is advanced in liver reconstitution by stem cells and the repair of l
'"/>

Contact: Jonathan Modie
modiej@ohsu.edu
503-494-8231
Oregon Health & Science University
23-Mar-2004


Page: 1 2 3 4 5

Related biology news :

1. New hypoxic event found off Oregon coast
2. Seven-foot living dinosaur lurks in Oregon
3. Oregon power companies offset carbon through investment in Ecuadors rainforest
4. ASPB urges opposition to mandatory labeling of genetically modified foods in Oregon
5. Oregon Health Sciences University researchers take steps to genetically modify monkeys for the research of human disease
6. Scientists gather in Oregon to decide next steps of mid-ocean ridge exploration
7. Oregon Scientists Discover A Second Blood-Brain Barrier; Important Finding For Patients With Brain Cancers And Neurological Disorders
8. USGS To Study Young Forests And Streamsides In Western Oregon
9. Testosterone And Working Memory; Epilepsy And Schizophrenia; Toxins And Neuron Death; Oregon Researchers Present Findings At Society For Neuroscience
10. NIH awards $18.2m to The Burnham Institute to develop Center on Proteolytic Pathways
11. Joslin Diabetes Center honors brothers living 70-plus years with type 1 diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Oregon Stem Cell Center result OHSU research strides

(Date:10/15/2014)... increased resistance to bacterial pneumonia in female mice to ... , Females are naturally more resistant to respiratory infections ... shown that increased resistance to bacterial pneumonia in female ... 3 (NOS3). They also show that this enzyme is ... hormone estrogen. , The team, lead by Professor Lester ...
(Date:10/14/2014)... Cancer Research shows SIRT6—a protein known to inhibit ... development of skin cancers by turning on an enzyme ... cells. , Previously considered protective, SIRT6 is part of ... regulate genomic stability and prevent some of the genetic ... which can lead to cancer. This study, in the ...
(Date:10/14/2014)... October 14, 2014 – High doses of fish oil supplements, ... a common type of irregular heartbeat in which the heart ... results of the AFFORD trial led by the Montreal Heart ... College of Cardiology on October 7th. , For the ... therapy were randomly assigned to 4 grams of fish oil ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... Hill, SC (PRWEB) October 22, 2014 ... expansion of its cardiovascular pharmacogenetics menu, which enables ... patient outcomes. With PCLS’s evidence-based results, healthcare ... needs and optimize their therapy, while minimizing risks ... In the U.S., according to the FDA [1] ...
(Date:10/22/2014)... 2014 Research and Markets  has announced ... Material, by Application, Geography - Global Analysis and Forecast ... Organic electronics, also called as polymer electronics ... which deals with small conductive molecules and electrically conductive ... and polymers are carbon based, made using synthetic strategies ...
(Date:10/20/2014)... , Oct. 20, 2014 Asterias ... the Company has signed a Notice of Grant ... Medicine (CIRM), effective October 1, 2014.  The NGA ... payments and the release of additional grant funds ... grant award for clinical development of Asterias, product, ...
Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4
Cached News: